GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
73.25
+0.53 (+0.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close72.72
Open72.79
Bid73.13 x 100
Ask73.72 x 200
Day's Range72.47 - 73.56
52 Week Range63.76 - 89.54
Volume6,335,525
Avg. Volume7,931,562
Market Cap95.507B
Beta1.35
PE Ratio (TTM)20.87
EPS (TTM)3.51
Earnings DateMay 1, 2018
Forward Dividend & Yield2.28 (3.03%)
Ex-Dividend Date2018-03-15
1y Target Est89.05
Trade prices are not sourced from all markets
  • Investopedia57 minutes ago

    Why Gilead's Stock Bulls Are Wrong

    Gilead Sciences Inc.'s ( GILD) bulls may be dreaming when it comes to their price targets that on average see the stock rising by over 21.5% to $88.75, based on data from Ycharts. The big price targets come as earnings are forecast to have a significant drop in 2018, while the stock trades at one of its highest forward PE multiple in years. Analysts have also become increasingly more bullish throughout the year as well, but earnings and revenue estimates haven't improved in a material way.

  • Reuters13 hours ago

    U.S. court upholds dismissal of $200 mln Merck verdict against Gilead

    A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc. The U.S. Court of Appeals for the Federal Circuit upheld a June 2016 ruling that the two Merck patents, which cover methods of treating Hepatitis C, were unenforceable because of a pattern of misconduct by the company, including lying under oath by one of its in-house lawyers.

  • Gilead Sciences has a Strong Oncology Research Program
    Market Realist22 hours ago

    Gilead Sciences has a Strong Oncology Research Program

    Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist22 hours ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist23 hours ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress
    Market Realist23 hours ago

    Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress

    Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.

  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realist2 days ago

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing
    Motley Fool2 days ago

    Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing

    If you're an investor who's heard of zinc-finger proteins and gene editing but you aren't sure what it all means, this can help answer your questions.

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • Is Bellicum Pharmaceuticals, Inc. a Buy?
    Motley Fool2 days ago

    Is Bellicum Pharmaceuticals, Inc. a Buy?

    Bellicum Pharmaceuticals may appear like a bargain, but a deeper dive suggests otherwise.

  • This Small Biotech Is Building on a Surprising Success
    Motley Fool2 days ago

    This Small Biotech Is Building on a Surprising Success

    Enanta Pharmaceuticals helped AbbVie score big last year. Now it's setting its sights even higher.

  • 3 Bargain Stocks You Can Buy Right Now
    Motley Fool2 days ago

    3 Bargain Stocks You Can Buy Right Now

    The market is giving investors great long-term opportunities on the cheap with these three stocks.

  • Can Gilead Sciences Inc’s (NASDAQ:GILD) ROE Continue To Surpass The Industry Average?
    Simply Wall St.3 days ago

    Can Gilead Sciences Inc’s (NASDAQ:GILD) ROE Continue To Surpass The Industry Average?

    Gilead Sciences Inc (NASDAQ:GILD) delivered an ROE of 22.65% over the past 12 months, which is an impressive feat relative to its industry average of 17.87% during the same period.Read More...

  • Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
    Zacks3 days ago

    Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

    Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

  • Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)
    Motley Fool4 days ago

    Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)

    Which stock wins in a match-up between these huge drugmakers?

  • Exploring the Financial Performance of Sarepta Therapeutics
    Market Realist5 days ago

    Exploring the Financial Performance of Sarepta Therapeutics

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.

  • Forbes5 days ago

    8%+ Dividends From My Favorite Sector Now

    I want to show you a beaten-down sector that has a long history of crushing the market—and 4 funds that should be on your radar now.

  • The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

    The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

  • Barrons.com6 days ago

    [$$] Big Buys in Alphabet, Facebook for Hot Hedge-Fund Manager

    Antipodes is also quite contrarian. Antipodes is located Down Under, but its performance has been Up Above. The Antipodes Global Fund-Long Only, the Antipodes Global fund, and the Antipodes Asia fund all adopted new strategies on June 30, 2015, and since then, through the first quarter of 2018, they are up 44.9%, 42.4%, and 34.4%, respectively, in absolute performance.

  • Top Research Reports for IBM, McDonald's & Gilead
    Zacks7 days ago

    Top Research Reports for IBM, McDonald's & Gilead

    Top Research Reports for IBM, McDonald's & Gilead

  • MarketWatch7 days ago

    Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

    Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...

  • Analysts’ Recommendations for Exelixis in April 2018
    Market Realist7 days ago

    Analysts’ Recommendations for Exelixis in April 2018

    In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist7 days ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • PR Newswire8 days ago

    Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

    TOKYO, April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, "Kite"), today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realist8 days ago

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...